296 related articles for article (PubMed ID: 33749761)
21. [Pitfalls of monoclonal gammopathy].
Meuleman N
Rev Med Brux; 2013 Sep; 34(4):335-8. PubMed ID: 24195249
[TBL] [Abstract][Full Text] [Related]
22. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
[TBL] [Abstract][Full Text] [Related]
23. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
25. Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance.
Ryu AJ; Kumar S; Dispenzieri A; Kyle RA; Rajkumar SV; Kingsley TC
Blood Cancer J; 2023 Feb; 13(1):28. PubMed ID: 36797276
[TBL] [Abstract][Full Text] [Related]
26. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
28. Multimorbidity in patients with monoclonal gammopathy of undetermined significance.
Epstein MM; Zhou Y; Castaneda-Avila MA; Cohen HJ
Int J Cancer; 2023 Jun; 152(12):2485-2492. PubMed ID: 36799553
[TBL] [Abstract][Full Text] [Related]
29. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
32. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
33. Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study.
Ashruf OS; Orozco Z; Kaelber DC
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):626-632. PubMed ID: 37208255
[TBL] [Abstract][Full Text] [Related]
34. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
35. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
Goyal G; Rajkumar SV; Lacy MQ; Gertz MA; Buadi FK; Dispenzieri A; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kourelis TV; Warsame R; Kyle RA; Kumar SK
Leukemia; 2019 May; 33(5):1273-1277. PubMed ID: 30787429
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal gammopathy of undetermined significance (MGUS) manifestation in CNS: a regular or chance occurrence?
Prakhova L; Lebedev V; Ilves A; Nazinkina Y
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33762271
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
[TBL] [Abstract][Full Text] [Related]
38. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Iwanaga M; Tomonaga M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]